In terms of in vivo administration of activated NK cells, to our knowledge no studies have been conducted in CML patients, however use of NK stimulating agents such as IL-2 [52,53], and roquinimex [54], has been performed with some clinical benefit, although at present these therapies have not been optimized. The gene discussed is IL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.